Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RVTY gained 13.3% after Q2 adjusted EPS of $1.41 beat the $1.23 consensus on $730 million of revenue, prompting higher full-year revenue and profit guidance. Diagnostics, AI-enabled drug discovery and the SuperFlex launch add product momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Modest Returns ⢠Coverage Pressure RVTY has strong liquidity and cash flow but faces modest returns, weaker interest coverage, high intangible exposure, and increasingly expensive valuation multiples.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Strong breakout ⢠Stretched momentum Support Level: $124â$125 Resistance Level: $129.71 RVTY gained about 14% over the last month with strong momentum above $124â$125, but its RSI near 74 suggests a pullback risk unless it sustains a break above $129.71.
Sentiment & News
Key News Insights: ⢠Earnings Outlook Raised ⢠AI Demand Growth ⢠Prenatal Platform Launch Revvity's earnings beat, raised outlook, AI-driven demand and new prenatal platform signal strengthening growth momentum.
AI Summary
RVTY's Q2 beat and raised outlook strengthen its earnings-recovery case, led by high-growth, high-margin Diagnostics and robust cash flow, but its premium valuation already assumes broader growth that remains unproven amid Life Sciences declines, Signals contract pressure, and one-time tariff benefits. Investors should await evidence of sustained Diagnostics momentum and a cross-portfolio recovery before adding at current levels.
Description
Revvity, Inc. supplies instruments, reagents, software and laboratory services across diagnostics, life sciences research and applied markets globally through two reporting segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions unit sells research tools, informatics, imaging and analytical technologies used in academic and industrial research, environmental testing, food and agricultural applications, and industrial process monitoring, while the Diagnostics segment provides assay platforms, tests and supporting software for genetic and infectious disease screening and for genomic workflows in oncology and drug discovery. The company serves pharmaceutical and biotech firms, clinical and public health laboratories, academic institutions, healthcare providers and government agencies; it was founded in 1937, is headquartered in Waltham, Massachusetts, and changed its name from PerkinElmer in April 2023.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 1 | Sep 8 | RVTY | Revvity, Inc. | RVTY gained 13.3% after Q2 adjusted EPS of $1.41 beat the $1.23 consensus on $730 million of revenue, prompting higher full-year revenue and profit guidance. Diagnostics, AI-enabled drug discovery and the SuperFlex launch add product momentum. | Active | +0.0% |